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TheTGF-βpathwaycontrolsabroadrangeofcellularbehaviorincludingcellproliferation,diﬀerentiation,andapoptosisofvarious
cell types including tumor cells, endothelial cells, immune cells, and ﬁbroblasts. Besides TGF-β’s direct eﬀects on tumor growth
and its involvement in neoangiogenesis have received recent attention. Germline mutations in TGF-β r e c e p t o r so rc o r e c e p t o r s
causing Hereditary Hemorrhagic Teleangiectasia and the Loeys-Dietz syndrome underline the involvement of TGF-β in vessel
formation and maturation. Several therapeutic approaches are evaluated at present targeting the TGF-β pathway including
utilization of antisense oligonucleotides against TGF-β itself or antibodies or small molecule inhibitors of TGF-β receptors. Some
of these therapeutic agents have already entered the clinical arena including an antibody against the endothelium speciﬁc TGF-β
class I receptor ALK-1 targeting tumor vasculature. In conclusion, therapeutic manipulation of the TGF-β pathway opens great
opportunities in future cancer therapy.
1. TGF-β Pathway
The TGF-β superfamily consists of over 30 structurally
related multifunctional proteins, including three TGF-β
isoforms (TGF-β1, 2, and 3), three forms of activin, and
over 20 bone morphogenic proteins (BMPs), which control
a broad range of cellular behavior such as cell growth,
diﬀerentiation and apoptosis in various cell types including
tumor, immune, and endothelial cells as well as ﬁbroblasts
[1–5].
Ligand signaling is mediated through two related single
transmembrane type I and type II receptors, which together
comprise the only known family of serine/threonine kinases
[6–8]. In mammals, there are ﬁve diﬀerent type II (TGFBR2,
ActR-IIa, ActR-IIb, BMPR2, AMHRII) and seven type I
receptors, also named activin receptor-like kinases (ALK-
1-7) [7, 9]. In most cases, the receptor combination is
important for the binding of a speciﬁc ligand, but the
TGF-β family members often bind to more than one type
II and type I receptor combination [10]. Upon ligand
binding, the type I and type II receptors form a heteromeric
complex, presumably consisting of two type I and two type
I Ir e c e p t o r s .T h et y p eI Ir e c e p t o re x h i b i t sac o n s t i t u t i v e l y
active kinase which transphosphorylates and activates the
type I receptor in a glycine- and serine-rich region known
as GS-box [11]. The activated type I receptor propagates the
downstream signaling by phosphorylating speciﬁc receptor-
regulated SMAD proteins (R-SMAD) [12, 13]. R-SMADs
interact with SMAD-4, the only known common mediator
SMAD (CoSMAD) in mammals, and form heteromeric
complexes which translocate to the nucleus where they
inﬂuence gene expression (by binding to the DNA and acting
as transcription factors, coactivators, and corepressors) [14–
17].
The TGF-β pathway has several feedback mechanisms,
which regulate the duration of the signaling. One of the
feedback mechanisms is mediated by inhibitory SMADs (I-
SMAD), in humans SMAD-6 and SMAD-7, which compete
with the R-SMADs for binding to the type I receptor, but
without the ability to transduce the downstream signal. I-
SMADs also recruit the E3 ubiquitin ligases SMAD ubiquitin
related factor-1 and -2 (Smurf-1 and -2), which ubiquitinate2 Journal of Oncology
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Figure 1: TGF-β signaling cascade. Upon ligand binding the con-
stitutively active kinase of the type II receptor transphosphorylates
and activates the type I receptor. Type III receptors lack any kinase
activity but they act as accessory receptors and facilitate ligand
binding to the type I and II receptors. Downstream signaling
is mediated via R-SMADs which are phosphorylated by the
activated type I receptor and form a complex with CoSMADs. This
complex translocates to the nucleus where it induces transcription
of downstream signaling. I-SMAD proteins represent important
negative feedback structures, since they can block the signaling via
competitive binding to the type I receptors or R-SMADs. R-SMAD:
receptor-regulated SMAD; CoSMAD: common mediator SMAD; I-
SMAD: inhibitory SMAD; TF: transcription factor.
the SMADs and type I receptors, resulting in protein degra-
dation [18–23].
In humans, two accessory TGF-β superfamily receptors
have been described which have a more indirect role in
TGF-β signaling: betaglycan and endoglin. The later is
mainly expressed in endothelial cells [24–26]. These type III
receptors are structurally related transmembrane receptors
with short intracellular domains that lack any enzymatic
motif but contain many serine and threonine residues. They
facilitate the binding of ligand to the type I and type
II receptors [27]. A soluble form of endoglin has been
described, most likely generated by proteolytic shedding,
that antagonizes the membrane bound form [28]. The
components of the TGF-β pathway are shown schematically
in Figure 1.
2. TGF-β SignalinginCancer
2.1. Hereditary Cancer Syndromes. Several hereditary cancer
syndromes with mutations in TGF-β superfamily mem-
bers are known. The autosomal dominant familial juvenile
polyposis syndrome (JPS) is the most common of the
hamartomatous syndromes which occurs with an incidence
of about one per 100.000 births [29]. Patients develop
numerous polyps not only in the colon or rectum but also in
the proximal gastrointestinal tract. Although most juvenile
polyps are benign, malignant transformation occurs with a
lifetime risk of colorectal carcinoma of approximately 70%.
In addition, the risk of pancreatic, gastric, and duodenal
carcinoma is increased [29]. Germline mutations in diﬀerent
members of the TGF-β superfamily have been described in
JPS. In every fourth patient a mutation in the type I receptor
ALK-3 (BMPR1A) is found [30]. In 15% of cases SMAD-
4i sm u t a t e d[ 30]. Furthermore, mutations in the endoglin
gene have been described, but the incidence is unknown
[31].
Hereditary nonpolyposis colorectal cancer (HNPCC)
is the most common hereditary predisposition for the
development of colorectal cancer. HNPCC results from
germline mutations within genes involved in the DNA
mismatch repair system, leading to microsatellite instability.
Since the TGFBR2 gene contains a 10-base pair polyadenine
repeat microsatellite sequence, it is an apparent target for
inactivation caused by errors of the DNA mismatch repair.
Indeed, a mutated form of TGFBR2 can be observed in up to
80% of colon cancer patients with HNPCC [32, 33].
The autosomal cancer syndrome Cowden Syndrome
(CS) and Bannayan-Riley-Ruvalcaba (BRR) disease are nor-
mally associated with a phosphatase and tensin homolog
(PTEN) gene mutation. However, in one patient with CS
and BRR symptoms but without PTEN mutation an ALK-3
mutation was found [34].
2.2. Dysregulated Expression in Cancer Patients. For several
pathologies, especially cancer, a correlation between the
expression level of a TGF-β superfamily member and the
severity of the related disease has been identiﬁed, which
makes the concerning TGF-β family member a diagnostic,
prognostic, or predictive marker.
2.2.1. Transforming Growth Factors. In 1986, Nishimura et
al. detected elevated TGF-β levels in the urine of patients
suﬀering from advanced cancer stages compared to healthy
donors [35]. Since then, increased serum levels of TGF-β1
have been implicated as a prognostic marker of advanced
disease and poor prognosis in multiple cancer types such
as gastric carcinoma, colorectal cancer, bladder carcinoma,
prostate cancer, breast cancer, lung cancer, esophageal
adenocarcinoma, and melanoma [36–44]. But nevertheless
TGF-β levels are not yet used as tumor markers in clinical
routine.
2.2.2. Bone Morphogenic Proteins. Bone morphogenic pro-
teins can also serve as prognostic markers, since the BMP-
7 expression is increased in malignant melanomas and their
metastases, which correlates with a shorter time to tumor
recurrence [45]. Furthermore, high BMP-6 levels predicted
development of distant metastasis in primary prostate cancer
[46]. On the other hand, the mRNA level of BMP-2 was
signiﬁcantly decreased in breast cancer tumors compared to
normal breast tissue [47].Journal of Oncology 3
2.2.3. TGF-β Receptors. The expression of TGF-β superfam-
ily receptors within tumor cells can be a prognostic marker.
Reduced ALK-5 and TGFBR2 expression correlates with
a shorter survival rate of colon cancer patients, as does
reduced expression of the coreceptor betaglycan in breast
and prostate cancer patients [48–50]. Low expression levels
of TGFBR2 have been observed in patients with chronic
myeloid leukemia [51]. In addition, mutations in ALK-5
and TGFBR2 have been described for other haematological
malignancies, but it seems to be a rare event [52, 53]. A
signiﬁcant association between loss of BMPR2 expression
and tumor grade was found in bladder transitional cell
carcinoma [54]. In contrast, high expression of type III
coreceptorendoglin wasmainlydetectedonimmatureblood
vessels in prostate tumors and had a negative impact on
p a t i e n t ’ ss u r v i v a la sw e l la sw i t hr e s p o n s er a t e si nb r e a s t
cancer or cervical cancer [55–58]. Calabro et al. detected
elevated levels of soluble endoglin that correlated with low
TGF-β1 levels in patients with acute myeloid leukemia or
chronic myeloproliferative disorders [59]. However none of
these markers is used in routine clinical practice.
3. TGF-β SignalinginEndothelialCells
Several members of the TGF-β superfamily are expressed
in endothelial cells and play an important role in angio-
genesis and vasculogenesis. The targeted inactivation of
TGF-β signaling components in mice revealed the pathway’s
crucial role in vascular morphogenesis. For example, ani-
mals lacking TGF-β1, ALK-5, ALK-1, endoglin, or various
SMAD proteins die at midgestation during embryogenesis
due to defects in vascular development of the yolk sac
[10, 60–62].
In humans, the Hereditary Hemorrhagic Teleangiectasia
(HHT, also named Rendu-Osler-Weber syndrome) is an
autosomal dominant disease in which vascular dysplasia
results in teleangiectasia and arteriovenous malformations.
Two forms with diﬀerent clinical characteristics have been
described: HHT type 1 patients have a mutation in the
endoglin gene whereas HHT type 2 is characterized by
a mutation in the ALK-1 gene. Together these mutations
account for about 80% of all HHT patients [6, 63–65]. In
2005, another autosomal dominant syndrome with muta-
tions in TGF-β receptors was described: the Loeys-Dietz
syndrome. Patients have a very high risk for aortic dissection
or rupture. Analysis of 52 families with a history of Loeys-
Dietz syndrome revealed somatic mutations either in the
type I receptor ALK-5 or in the type II receptor TGFBR2
[66, 67].
3.1. Functional Aspects of TGF-β Signaling in Endothelial
Cells. In endothelial cells the type I TGF-β receptors, which
have been investigated most thoroughly, are ubiquitously
expressed ALK-5 and endothel-speciﬁc ALK-1. Previously,
it was believed that ALK-5 and ALK-1 had opposite roles
in angiogenesis and might balance the activation state
of endothelium. Several investigators observed increased
proliferationandmigrationwhentheTGF-β/ALK-1pathway
had been stimulated whereasstimulation of the TGF-β/ALK-
5 pathway led to inhibition of endothelial cell proliferation
and migration [68, 69]. This opposing eﬀect was thought
to be mediated by activation of SMAD-1/5/8 by ALK-1 and
SMAD-2/3 by ALK-5 [68]. Due to activation of diﬀerent
intracellular pathways, speciﬁc changes in gene transcription
can be observed. Goumans et al. revealed that the inhibitor
of DNA binding 1 (ID-1), a helix-loop-helix (HLH) protein
that can form heterodimers with members of the basic HLH
family of transcription factors, is a speciﬁc downstream signal
of ALK-1, whereas the proteinase inhibitor plasminogen
activator inhibitor-1 (PAI-1) is induced by ALK-5 activation
[68].
More recently published data might alter the presumed
relationship between ALK-1 and ALK-5. David et al. showed
that not TGF-β1 but the bone morphogenic proteins 9
and 10 are likely to be the physiological ligands for ALK-
1. Binding of BMP-9 to the ALK-1 and BMPR2 complex
potently inhibited endothelial cell proliferation and migra-
tion [70]. The increase of angiogenesis in ECs upon ALK-
1 activation in former studies was due to TGF-β1 binding
to the ALK-1/TGFBR2 complex. Thus, the role of ALK-
1 is dependant of type II receptor expression and ligand
availability. Interestingly, both pathways signal via activation
of SMAD-1, -5, and -8 although these SMADs have been
described as characteristic BMP downstream signals [71].
Hence, additional elements must be involved in regulation
of the ALK-1 pathway driving it either to the pro or
antiangiogenic direction. Indeed, cross-talk between the
TGF-β pathway with other pathways such as the mitogen-
activated protein kinase (MAPK), the phosphatidylinositol-
3 kinase (PI3K) or the Hedgehog pathways have been
described [72].
Very recently, a possible explanation for the requisite role
of ALK-1 and ALK-5 in angiogenesis has been described.
Shao et al. demonstrated that ALK-1 and ALK-5 are both
essential for the regulation of vascular endothelial growth
factor (VEGF), which is believed to be the central growth
factor in angiogenesis. TGF-β1/ALK-5 stimulation elevated
the m-RNA levels of VEGF in bovine aortic ECs, whereas
BMP-9/ALK-1 stimulation led to decreased VEGF m-RNA
levels. Proliferation and migration assays were in line with
these observations [73].
A remaining question is the interdependence between
ALK-1 and ALK-5. Whereas Goumans et al. proposed that
ALK-5 mediates a TGF-β-dependent recruitment of ALK-1
into the receptor complex and that ALK-5 kinase activity is
essentialforoptimalALK-1activity[68].Shaoetal.observed
opposite eﬀects. They found some hints that ALK-1 acts
independently of ALK-5 but that ALK-5 might actually be
dependent of ALK-1 [73]. Hence, interdependence between
ALK-1 and ALK-5 seems to be apparent, yet it has to be
clariﬁed which of the receptors is the leading force.
4. TGF-β Receptor Expressionin Leukemia
Since endothelial and hematopoietic cells have a common
stem cell, the so-called hemangioblast, many immature4 Journal of Oncology
hematopoieticcellssharecellsurfacereceptorswithendothe-
lial cells, such as receptors for hematopoieitc growth factors,
for example, GM-CSF or erythropoietin [74, 75]. Our group
investigated expression of ALK-1 and ALK-5 in various
leukemic cells lines and samples from patients with acute
myeloid leukemia (AML). We found that both receptors are
expressed in most cases implying that both ALK-1 and ALK-
5 are involved in autocrine or paracrine growth stimulation
in AML (manuscript in preparation).
In a recent study, an association between high ID-1
expression and poor prognosis in patients with AML has
been described. ID-1 is the typical downstream mediator of
ALK-1 signaling although enhancement of ID-1 expression
by other tryrosine kinase receptors such as FLT3 cannot be
excluded in a subgroup of patients [76]. However, data about
dysregulated TGF-β signaling in hematologic malignancies
are rare, since only few reports in lymphoid neoplasms or
myeloid leukemia have been published [52, 53, 77, 78].
5. TGF-β SignalingPathway as
aT h e rape u ticT arg et
Because of the enormous number of observed alterations in
the TGF-β pathway in cancer patients, the development of
therapeutic substances seems to be evident.
In fact, there are diﬀerent reasons why the inhibition
of the TGF-β pathway might be a promising target for
anticancer therapies. First, the direct eﬀect on tumor cells
has to be stressed. Secondly, as described above, the TGF-β
pathway plays an important role in endothelial cell behavior
and therefore in angiogenesis. Antiangiogenic therapies
belong to the most promising therapeutic concepts which
are currently under development. Thirdly, TGF-β is one
of the most potent naturally immunosuppressors [79, 80].
Mice deﬁcient for TGF-β1 develop a harmful syndrome with
multifocal, mixed inﬂammatory cell response, and tissue
necrosis,leadingtoorganfailureanddeath[4].Furthermore,
suppression of TGF-β signaling in T cells by transduction
with a truncated TGFBR2 resulted in severe autoimmune
reactions [81]. The immune response of cancer patients is
often suppressed, since many advanced tumors overexpress
TGF-β resulting in inhibition of IL-2-dependant prolifer-
ation and diﬀerentiation of NK and T cells [82, 83]. In
addition, TGF-β recruits diﬀerent immune cells to the tumor
microenvironment: monocytes and macrophages promote
tumor invasion, angiogenesis and metastasis whereas mast
cells secrete numerous tumor promoting factors [83].
Figure 2 summarizes the main tumor promoting eﬀects of
dysregulated TGF-β signaling.
Targeting the TGF-β pathway should therefore not only
aﬀect the tumor cells by itself; moreover a decreased tumor
vascularization and strengthening the patient’s immune
responses should be achieved. Numerous in vitro and in
vivo studies have been performed, accounting for these
diﬀerent strategies to inhibit tumor growth and to target
various components within the TGF-β pathway including
ligands, receptors and even downstream signals. Some of
these studies passed the preclinical phase with success and
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Figure 2: Dysregulation of the TGF-β pathway promotes tumor
growth. An unbalanced TGF-β pathway can cause advanced
tumorigenesis due to several cellular changes. On the one hand,
the dysregulation has a direct eﬀect on tumor cells leading to
elevated tumor cell proliferation. Secondly, endothelial cells are
aﬀected which results in increased angiogenesis and therefore in
tumor vascularization. Finally immune responses are attenuated
due to inhibition of T cell proliferation and migration caused by
dysregulated TGF-β signaling.
phase I and II clinical studies have been started. Table 1
gives a short overview of preclinical and clinical studies using
agents targeted at TGF-β family members.
Representing the central factor of the pathway, TGF-β is
the preferred target structure in most cases. For example,
Yang et al. developed transgenic mice expressing a TGF-β
antagonist consisting of a soluble TGF-β type II receptor
fused with the Fc domain of a human IgG1. The number of
metastases was reduced both in a tail vein metastasis assay
with melanoma cells and in crosses with a transgenic mouse
model of metastatic breast cancer [101]. A neutralizing pan-
TGF-β antibody prevented radiation-induced acceleration of
metastatic cancer progression in a transgenic mouse model
of metastatic breast cancer [102]. The pan-TGF-β antibody
GC-1008 was tested in a phase I clinical study with 22
patients with renal cell carcinoma or malignant melanoma
(NCT00356460). Treatment was well tolerated with mainly
grade 1-2 toxicity including skin rash, fatigue, headache
and gastrointestinal symptoms. 5 patients achieved stable
disease or better and one patient with skin disease achieved
a partial response with >75% reduction of target lesions
[84].
Several studies concentrated on the restoration of
immune responses. In a prostate cancer xenograft model a
reduction in tumor weight was observed after implantation
oftumor-reactiveCD8+ TcellswhichwereTGF-β insensitive
due to introduction of a dominant-negative TGF-β type
II receptor vector [103]. Yamamoto et al. utilized direct
hemoperfusion treatment with speciﬁc immunosuppres-
sive substance adsorption columns for TGF-β ablation in
rats bearing a TGF-β-producing hepatocellular carcinoma.
TGF-β serum levels were decreased after hemoperfusion
treatment leading to restored T lymphocyte response,Journal of Oncology 5
Table 1: Overview of preclinical and clinical studies using agents targeted at TGF-β family members.
Class of substance Target Drug Study
Human anti-TGF-β mAb TGF-β GC1008 Phase I study on renal cell carcinoma and malignant
melanoma (NCT00356460 and NCT00899444) [84]
TGF-β2 antisense compound TGF-β2 AP12009
Phase I study on pancreatic and colorectal neoplasms
and melanoma (NCT00844064)
Phase II study on glioblastoma and anaplastic
astrocytoma (NCT00431561) [85, 86]
Phase III study on anaplastic astrocytoma
(NCT00761280)
Belagenpumatucel-L Phase II study on advanced nonsmall lung cancer
(NCT01058785) [87]
TGF-β type I and type II receptor
small molecule inhibitor
TGF-β type I
and type II
receptors
LY2109761 Preclinical studies [88–94]
Human anti-ALK-1 mAb ALK-1 PF-03446962 Phase I on advanced solid tumors (NCT00557856)
ALK-5 small molecule inhibitor ALK-5
SB431542 Preclinical studies [95, 96]
SD208 Preclinical studies [97, 98]
SM16 Preclinical studies [78, 99]
Chimeric antiEndoglin antibody Endoglin TRC105 Phase I on advanced or metastatic solid cancer
(NCT00582985) [100]
decelerated tumor growth and longer survival times [104].
Fujita et al. observed similar results using plasmid DNA
encoding the extracellular domain of the TGF-β type II
receptor fused to the human IgG heavy chain; after plasmid
injection in the proximity of established murine lymphomas
an increased number of tumor antigen-speciﬁc CD4+ and
CD8+ cellscouldbedetectedintumor-draininglymphnodes
[105].
Another promising approach which has entered clinical
phase I and II trials is to inhibit TGF-β function by means
of antisense oligonucleotides (AS-ODNs). In a preclinical
trial, local intracranial administration of TGF-β2A S - O D N s
was combined with systemic tumor vaccine in a rat glioma
model. Only the combination of both substances led to
a signiﬁcantly prolonged survival [106]. Increased survival
of glioma patients who had received whole-cell vaccines
comprising autologous tumor cells genetically modiﬁed by
aT G F - β2 antisense vector was observed in a phase I
study [107]. A phase II trial with belagenpumatucel-L, a
TGF-β2 antisense gene-modiﬁed allogeneic tumor vaccine,
is ongoing in patients with advanced nonsmall cell lung
cancer (NCT01058785) [87]. The antitumorigenic eﬀect of
antisense oligonucleotides was supported by phase II trials
with the TGF-β2 inhibitor AP12009. In comparison to
standard chemotherapy, treatment with AP12009 resulted in
prolonged survival of patients with anaplastic astrocytoma
[85]. Consistently, patients with high-grade glioma achieved
a higher survival rate at 24 months and showed signiﬁcantly
more responders after 14 months when AP12009 treat-
ment was compared to standard chemotherapy protocols
[86].
Therapeutic concepts against TGF-β receptors were
almost exclusively targeted at ALK-5, in most cases using
small molecule inhibitors such as SB431542 which showed
similar results in several in vitro and in vivo stud-
ies. SB431542 caused inhibition of proliferation, TGF-β-
mediated morphognic changes, and cellular motility of
glioma cells in vitro. This eﬀect was due to blocked
phosphorylation of SMADs leading to reduced transcription
of PAI-1 and VEGF which are key mediators in cell invasion
and neoangiogenesis [95]. Javelaud and collegues analyzed
the role of TGF-β in murine melanoma metastasis to bone.
BoththetherapywithSB431542aswellastumorstransduced
with the inhibitory protein SMAD-7, showed signiﬁcantly
less osteolyses, longer survival and lower expression levels
of osteolytic factors such as parathyroid hormone-related
protein and interleukin-11 [96].
Another ALK-5 small molecule inhibitor, SD208, led
to decreased tumor growth and metastasis in a murine
mamma carcinoma and pancreatic adenocarcinoma model.
Furthermore, antiangiogenic eﬀects could be observed in
both studies with a reduced microvessel density and altered
expression levels of angiogenesis-related factors like FLT-
1, Neuropillin-2 and VEGF-C, respectively [97, 98]. In
addition, treatment of CD34+ cells isolated from patients
with myelodysplastic syndrome with SD208 led to in vitro
enhancement of hematopoiesis [78]. Furthermore in a
malignant mesothelioma mouse model, the ALK-5 inhibitor
SM16 signiﬁcantly decreased tumor growth which could be
ascribed to a CD8+ antitumor response [99].
The substance LY2109761 inhibits both TGF-β type I
and type II receptors [88]. An orthotopic murine model of
metastatic pancreatic cancer and a liver metastasis model
proved the eﬃcacy of LY2109761, since tumor growth and
spontaneous metastases were reduced whereas the animals’
survival was prolonged [89]. Similar eﬀects were observed
in an experimental colorectal cancer mouse model [90].
Gianelli’s group performed several studies with LY21097616 Journal of Oncology
in hepatocellular carcinoma. Tumor progression was delayed
due to inhibition of vascular invasion as well as disturbance
of cross-talk between hepatocellular carcinoma cells and
stroma or endothelial cells. In a xenograft chick embryo
model, LY210976 treatment caused even enhanced inhi-
bition of tumor growth and reduced microvessel density
compared to bevacizumab-treated animals. However, the
strongest antitumoral eﬀect was observed when combining
both substances [91–93]. Myelo-monocytic leukemic cells
cocultured with bone marrow derived mesenchymal stem
c e l l sw e r es t i m u l a t e dw i t hT G F - β1 which led to inhibition
of spontaneous and cytarabine-induced apoptosis. This
prosurvival signaling was neutralized with LY2109761 [94].
AlthoughnoinvitrodataaboutspeciﬁcALK-1inhibitors
have been published so far, a clinical phase I study testing a
human antiALK-1 antibody in patients with advanced solid
tumors is ongoing (NCT00557856).
Since its expression is restricted to endothelial cells with
higher expression levels in tumor-associated endothelium
compared to normal tissue, the accessory receptor endoglin
may represent a promising target for anticancer therapy
[108]. Antitumorigenic and antiangiogenic eﬀects could be
observed in several in vivo tumor models using antiendoglin
antibodies [109–112]. For example, Uneda et al. used
multiple metastasis models with murine mamma carcinoma
and colon adenocarcinoma cells to test the eﬀect of sev-
eral antiendoglin antibodies targeted at diﬀerent endoglin
epitopes. Under treatment, metastases were suppressed and
microvessel density was eﬀectively reduced as measured by
Matrigel plug assay [109, 113]: a phase I clinical trial with the
human/murine chimeric antiendoglin monoclonal antibody
TRC105 in 19 patients with solid cancer. Treatment was well
tolerated with mainly grade 1-2 toxicity including fatigue,
anemia,proteinuriaanddiarrhea.Onepatientwithhormone
refractory prostate cancer obtained a complete PSA response
and 3 patients had prolonged stable disease (NCT00582985)
[100].
6. Outlook
The results of numerous in vitro studies with cell lines,
in vivo mouse models and clinical trials show that the
TGF-βpathwayplaysanimportantroleincancerprogression
and represents a promising target for anticancer therapy.
Targeting TGF-β isoforms, TGF-β r e c e p t o r sa sw e l la s
downstream signaling proteins yielded satisfactory results,
s i n c ear e d u c t i o ni nt u m o rl o a dw a so b s e r v e di nm o s tc a s e s .
Manipulating TGF-β signaling implies the great advan-
tage of aﬀecting at least three important structures in
tumor progression: in addition to the direct antitumor
eﬀect, endothelial and immune cells will be targeted.
Although restoration of the immune system is a desirable
achievement in cancer therapy, the complete inhibition of
TGF-β1 might have fatal consequences. For example, TGF-
β1 deﬁcient mice develop a lethal syndrome accompanied
by a multifocal, mixed inﬂammatory cell response and
tissue necrosis, leading to organ failure [4]. Furthermore,
abrogation of TGF-β signaling in T cells by introduction of
a truncated TGFBR2 results in severe autoimmune reactions
[81].
In addition, TGF-β1 plays an important role in ﬁbroblast
biology, since it is a relevant growth factor for extracellular
matrix formation in ﬁbroblasts due to its stimulation of
collagen, ﬁbronectin and proteoglycan synthesis [114]. Due
to TGF-β signaling, ﬁbroblasts suppress the activation of
tumor-promoting paracrine signaling which would target
epithelial cells and could lead to epithelial to mesenchymal
transition [115]. Bhowmick et al. inactivated the TGFBR2
gene in mouse ﬁbroblasts which resulted in intraepithelial
neoplasia in prostate and invasive squamous cell carcinoma
of the forestomach [115]. Coimplantation of TGFBR2-
deﬁcient mammary ﬁbroblasts with mammary carcinoma
c e l l sp r o m o t e dt u m o rg r o w t ha n di n v a s i o na sc o m p a r e dt o
wild-type ﬁbroblasts [116].
These examples reveal the great diﬃculty in targeting the
TGF-β pathway. Perhaps targeting the type I receptor ALK-1
ortheaccessoryreceptorendoglinmightrepresentasolution
to this discrepancy since expression of both receptors seems
to be restricted to endothelial cells which could limit side
eﬀects. Therefore, results of phase I studies are awaited
where patients with advanced solid tumors will be treated
with an ALK-1 or an endoglin antibody (NCT00557856
and NCT00582985, resp.). These studies might resolve this
question.
Integrating all results underlines the complexity in
TGF-β signaling in endothelial cells. In some extent, this
may be due to diﬀerent experimental settings since TGF-β
superfamily members have often been overexpressed or
downregulated in in vitro models using plasmid vectors.
Furthermore, although discussed as important ALK-1 ligand
intheregulationofangiogenesis,nophysiologicaldataabout
BMP-9 or BMP-10 expression in endothelial or tumor cells
exist.
7. Conclusion
We conclude that the TGF-β pathway might be a promis-
ing therapeutic target in anticancer therapy due to its
involvement in several mechanisms including endothelial
and immune cell biology that are most important for
tumor progression. On the other hand, since the TGF-
β pathway aﬀects a broad range of cellular behavior, it
is an ambitious approach to restore the delicate balance
of physiological signaling. Therefore manipulation of the
pathway bears the risk of adverse eﬀects and of therapeutic
success. Comprehensive investigations that comprise the
interactionsbetweentumorcells,ﬁbroblasts,endothelialand
immune cells are indispensable.
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